Sukumar Nagendran - 23 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and Head of R&D, Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
23 Jan 2026
Net transactions value
-$547,469
Form type
4
Filing time
27 Jan 2026, 16:05:16 UTC
Previous filing
14 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nagendran Sukumar President and Head of R&D, Director C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS /s/ Kamran Alam, Attorney-in-Fact 27 Jan 2026 0001665124

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Sale $423,377 -89,132 -6.2% $4.75 1,344,307 23 Jan 2026 Direct F1, F2
transaction TSHA Common Stock Sale $124,092 -26,918 -2% $4.61 1,317,389 26 Jan 2026 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.